The development of coagulopathy is emerging as one of the most significant poor prognostic features in COVID-19 pneumopathy . D-dimer, a protein product of fibrin degradation, has been found elevated in the most severe cases and correlated to mortality . Potentially involved factors in the impairment of coagulation caused by viral infection include the dysregulated inflammatory response, platelet and endothelial dysfunction with impaired fibrinolysis . Autoptic analysis in deaths fore severe COVID-19 disease revealed fibrin exudation in alveoli, blood vessel wall edema and hyaline thrombi in small vessels in other organs and tissues . Heparin is an anticoagulant molecule that also showed anti-inflammatory properties and a potential antiviral effect . The use of low molecular weight heparin could prevent thromboembolic complications in COVID-19 pneumopathy . However, the correct timing of prophylaxis according to the stage of COVID-19 disease and the appropriate therapeutic dosage to use in severe cases need further research.